Use of acetylcysteine as an adjuvant treatment for patients with acute organophosphorus pesticides poisoning

In adult patients with acute organophosphorus pesticides poisoning could the use of N-acetylcysteine besides the standard treatment compared to the use of the standard treatment alone reduce mortality?

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000407695

Enrollment

Registered

2014-04-15

Start date

2014-05-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will be carried out to evaluate the efficacy and safety of orally given acetylcysteine as an adjuvant treatment for adult patients with acute organophosphorus pesticide poisoning.

Interventions

N-acetylcysteine will be given orally, as a dose of 600 mg three times daily for three days. If the patient vomits any dose within 1 hour of administration, the dose will be repeated. Standard treatment: atropine administration (bolus dose of 2 to 5 mg IV, repeated every 10 to 15 minutes until dryness of bronchial secretions is clinically evident, then atropine injections will be given intermittently to patients as needed

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients (male or female, aged 18 years or older) with symptomatic acute OP poisoning (deliberate or accidental), with diagnosis made on the basis of the typical clinical toxidrome of cholinergic and nicotinic manifestations due to and following shortly after a single exposure to OP, besides reliable identification of the compound based on the container brought by patient attendants or a subsequent confirmation by pseudocholinesterase.

Exclusion criteria

- Patients who do not consent - Patients less than 18 years of age - Pregnant and lactating women - Patients with ingestion or exposure to other substances in addition to the OP - Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure) - Patients presenting more than 12 hours of having consumed the OP compound (late presenters)

Outcome results